Literature DB >> 9421315

Effect of levofloxacin, erythromycin or rifampicin pretreatment on growth of Legionella pneumophila in human monocytes.

R P Smith1, A L Baltch, M Franke, W Hioe, W Ritz, P Michelsen.   

Abstract

Opsonophagocytic killing of some bacteria (Staphylococcus aureus, Pseudomonas aeruginosa) by phagocytes is enhanced by previous brief exposure of the organism to antibiotics. We studied the regrowth of Legionella pneumophila previously pretreated with levofloxacin, erythromycin and/or rifampicin in human monocytes. The MIC for the L. pneumophila isolate of levofloxacin, erythromycin and rifampicin was 0.03, 0.5 and 0.001 mg/L, respectively. Growth of L. pneumophila from buffered charcoal yeast extract (BCYE) agar for 24 h was subcultured into BYE broth containing from 0 to 4x MIC of levofloxacin, erythromycin or rifampicin. After incubation at 35 degrees C in 5% CO2 for 18 h, the organisms were washed and opsonized with 20% heat inactivated pooled normal human serum. Thereafter, L. pneumophila was exposed to human monocytes (5:1 ratio) previously adhered to wells in tissue culture plates containing RPMI and 10% fetal calf serum. After 0, 24, 48 and 72 h of incubation, quantitative cultures of lysed human monocytes were done on BCYE agar. Our results indicate effective inhibition on L. pneumophila at 0 h regardless of the antibiotic (levofloxacin, rifampicin or erythromycin) or their concentrations (1x, 2x or 4x MIC). At 24, 48 and 72 h, recovery and regrowth of L. pneumophila were both antibiotic- and concentration-dependent. In comparison with controls (no antibiotic pretreatment), peak regrowth of L. pneumophila pretreated with either 1x MIC of levofloxacin or erythromycin was delayed (48 versus 24 h) and reduced (30% of control peak regrowth). Regrowth of L. pneumophila pretreated with 1x MIC of rifampicin continued beyond 72 h. Pretreatment with levofloxacin at 4x MIC caused the greatest degree of growth inhibition (2 log10). In contrast, at 72 h, regrowth of organisms pretreated with 4x MIC of erythromycin or rifampicin was less than peak control (P < 0.01) but greater than that seen with levofloxacin (P < 0.01). The rate and degree of regrowth of L. pneumophila pretreated with combinations of levofloxacin or erythromycin with rifampicin, or levofloxacin with erythromycin (all at 1x MIC) was similar to that seen with single drugs. Thus, significant delay and reduction of regrowth in this phagocytic system occurred with levofloxacin only. Prolonged exposure of the organism at 4x MIC levofloxacin concentrations was effective in suppressing regrowth of pretreated L. pneumophila in human monocytes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9421315     DOI: 10.1093/jac/40.5.673

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Detection of Legionella pneumophila on clinical samples and susceptibility assessment by flow cytometry.

Authors:  I Faria-Ramos; S Costa-de-Oliveira; J Barbosa; A Cardoso; J Santos-Antunes; A G Rodrigues; C Pina-Vaz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-07-28       Impact factor: 3.267

2.  Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila.

Authors:  A L Baltch; R P Smith; M A Franke; P B Michelsen
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

Review 3.  Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.

Authors:  H D Langtry; H M Lamb
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

4.  Use of the microbial growth curve in postantibiotic effect studies of Legionella pneumophila.

Authors:  Raymond P Smith; Aldona L Baltch; Phyllis B Michelsen; William J Ritz; Richard Alteri
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

5.  An investigation of virulence factors of Legionella pneumophila environmental isolates.

Authors:  Elif Özlem Arslan-Aydoğdu; Ayten Kimiran
Journal:  Braz J Microbiol       Date:  2017-07-22       Impact factor: 2.476

Review 6.  Legionnaires' disease: clinical differentiation from typical and other atypical pneumonias.

Authors:  Burke A Cunha
Journal:  Infect Dis Clin North Am       Date:  2010-03       Impact factor: 5.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.